1. A method of treating precancerous conditions in the cervix and vagina, or cancer in the cervix or vagina in a patient in need of treatment thereof, comprising:
administering to said patient an effective amount of a pharmaceutical composition comprising at least one substance with oxytocin activity,
wherein said at least one substance with oxytocin activity is of the formula:
or a salt thereof,
wherein:
X1 is Cys, Mpa or nothing;
X2 is Tyr, (O-Methyl)Tyr, Phe or nothing;
X3 is Ile, Val, Hoph, Phe, Cha or nothing;
X4 is Gln, Ser, Thr, Cit, Arg or Daba;
X5 is Pro or nothing;
X6 is Ile, Leu, Val, Hos, Daba, Thr, Arg, Cit or nothing;
X7 is Gly, Ala or nothing;
X8 is Gly or nothing; and
X9 is CH2 or S;
wherein the term \u201cnothing\u201d indicates that the letters X1 X2 X3 X4 X5 X6 X7 and X8 respectively have no meaning or represent a bond and that there is a direct bond between the letters, atom, or group situated to the right and to the left, respectiveiy, of the letter designated \u201cnothing\u201d.
2. The method according to claim 1, wherein said at least one substance is selected from the group consisting of the following compounds: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.
3. The method according to claim 1, wherein said pharmaceutical composition comprises substances that increase the release of oxytocin andor the number or affinity of oxytocin receptors or drugs having an \u03b12-agonistic effect.
4. The method according to claim 1, wherein said at least one substance is administered in amount of 0.01\u2013100 ngkg body weight of the patient.
5. The method according to claim 1, wherein said at least one substance is administered in amount of 0.1\u201310 ngkg body weight of the patient.
6. The method according to claim 3, wherein said drug having an \u03b12-agonistic effect is clonidine.
7. The method according to claim 3, wherein said substance that increases the release of oxytocin andor the number or affinity of oxytocin receptors is oestrogen.
8. The method according to claim 2, wherein said pharmaceutical composition comprises substances that increase the release of oxytocin andor the number or affinity of oxytocin receptors or drugs having an \u03b12-agonistic effect.
9. The method according to claim 8, wherein said drug having an \u03b12-agonistic effect is clonidine.
10. The method according to claim 1, wherein said substance comprises SEQ ID NO: 1.
11. The method according to claim 2, wherein said at least one substance is administered in amount of 0.01\u2013100 ngkg body weight of the patient.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A method of software execution, comprising:
executing a hardware simulation process that simultaneously executes plural different simulation processes with each simulation process having plural xterm windows;
receiving a selection of one of the simulation processes; and
automatically reducing or hiding xterm windows not associated with the one of the simulation processes in response to receiving the selection of one of the simulation processes.
2. The method of claim 1 further comprising, automatically transforming the xterm windows not associated with the one of the simulation processes into graphical icons.
3. The method of claim 1, wherein each of the plural different simulation processes has a control window, a console window, and an information window.
4. The method of claim 1 further comprising, receiving a focus command from a user that indicates the selection of the one of the simulation processes.
5. The method of claim 1, wherein the plural different simulation processes are interconnected to form a complete platform simulation.
6. The method of claim 1 further comprising:
generating the selection from user input at a control window simultaneously displayed with the plural xterm windows;
transmitting the selection to a control process that controls the windows not associated with the one of the simulation processes.
7. The method of claim 1 further comprising:
iconifying the xterm windows not associated with the one of the simulation processes;
redirecting input of the one of the simulation processes from a user control window to a window that controls the simulation process;
removing the user control window.
8. A method executed by a computer, comprising:
executing a hardware simulation process that simultaneously executes a first simulation process having an xterm window and a second simulation process having an xterm window;
simultaneously displaying the xterm window of the first simulation process and the xterm window of the second simulation process;
selecting to work with the first simulation process; and
automatically minimizing display of the xterm window of the second simulation process upon selecting to work with the first simulation process.
9. The method of claim 8, wherein the first and the second simulations processes each has three xterm windows that include an information window, a control window, and a console window, and selection to work with the first simulation process automatically minimizes display of the information window, the control window, and the console window of the second simulation process.
10. The method of claim 8 further comprising, running the second simulation in a background while the xterm window of the second simulation is minimized.
11. The method of claim 8 further comprising, receiving a focus command from a graphical user interface that indicates selection to work with the first simulation process.
12. The method of claim 8 further comprising:
generating a selection to work with the first simulation process from input at a control window simultaneously displayed with the xterm window of the first simulation process and the xterm window of the second simulation process;
transmitting the selection to a control process that minimizes display of windows not associated with the first simulation processes.